Ozempic Cost Per Shot: Pricing & Compounded Alternatives

Last reviewed: May 20, 2026

Last updated: May 20, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

A single Ozempic injection typically costs $250 to $900 without insurance, depending on the specific dosage strength (0.25 mg to 2.0 mg). Most patients receive prescriptions for multi-dose pens containing four injections, bringing monthly costs to $900–$1,400 before insurance copays. Understanding the full cost picture—including pharmacy variations, insurance coverage, and alternative formulations—is essential before committing to any GLP-1 therapy.

Choosing a GLP-1 medication involves more than price comparison. Clinical factors such as individual metabolic risk profiles, genetic predispositions in GLP-1 receptor signaling, and baseline cardiovascular or renal function should guide treatment selection. PlexusDx supports this precision approach by combining transparent pricing with biomarker context, helping patients and providers make informed decisions about branded versus compounded options.

Branded Ozempic Pricing and Dosage Structure

Ozempic is manufactured by Novo Nordisk and approved by the FDA for type 2 diabetes management. In the United States, the average wholesale price (AWP) for a single 0.5 mg injection ranges from $250 to $350. However, the medication is dispensed in multi-dose pens—not individual shots—containing 4 injections per pen.

A monthly Ozempic prescription (one pen) typically costs $900–$1,400 at retail pharmacies without insurance coverage. The total depends on local pharmacy pricing, manufacturer rebates, and patient assistance programs. Patients with commercial insurance usually pay $25–$250 per month via copay, while uninsured patients often qualify for Novo Nordisk's copay assistance, reducing out-of-pocket costs significantly.

Comparing Branded Ozempic, Wegovy, and Compounded Alternatives

Understanding the cost and clinical differences across GLP-1 options helps patients and providers align treatment selection with budget and clinical goals. The table below compares retail pricing, formulation type, and prescribing context for major GLP-1 solutions. Note that compounded medications are not FDA-approved but are prepared by licensed 503A pharmacies under state pharmacy board oversight.

Medication	Typical Monthly Cost	Formulation	Prescribing Context
Ozempic (branded semaglutide)	$900–$1,400	Pre-filled multi-dose pen	Type 2 diabetes, cardio protection
Wegovy (branded semaglutide)	$935–$1,350	Pre-filled multi-dose pen	Weight management, chronic use
Compounded semaglutide injection	$189	Individual vials, flexible dosing	Off-label, variable pharmacy practices
Compounded tirzepatide injection	$289	Individual vials, flexible dosing	Off-label, variable pharmacy practices

Insurance Coverage, Copay Assistance, and Patient Programs

Insurance coverage for Ozempic varies significantly by plan and indication. Medicare Part D may cover Ozempic for type 2 diabetes with step therapy requirements; Medicaid coverage depends on individual state programs. Commercial insurers increasingly cover GLP-1 medications, though many impose prior authorization, quantity limits, or dose escalation protocols to manage costs.

Novo Nordisk's official copay assistance program caps patient out-of-pocket costs at $250 per month for eligible individuals with commercial insurance. Uninsured patients may qualify for manufacturer-sponsored programs offering discounted pricing tiers. Hospital systems and large employers sometimes negotiate direct pricing with manufacturers, creating variation in actual patient costs not reflected in published retail prices.

Clinical Eligibility and Safety Considerations for GLP-1 Selection

GLP-1 receptor agonists like Ozempic carry important contraindications and monitoring requirements. Patients with a personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia type 2, or severe pancreatitis should not use GLP-1 drugs. Baseline assessment of renal function, cardiovascular status, and diabetic eye disease is recommended before initiation and during dose escalation.

Individual responses to GLP-1 therapy vary based on genetics, baseline metabolic phenotype, and concomitant medications. Some patients experience rapid and durable weight loss or glycemic improvement; others respond more gradually or experience dose-limiting side effects. This variability underscores the importance of working with a qualified provider to select the right medication, dosing strategy, and monitoring plan for your clinical profile.

How PlexusDx Supports a More Personalized Approach

PlexusDx's Precision Peptide Genetic Test may help provide context about individual predispositions in key GLP-1 receptor signaling pathways, including variants in GIPR genes. These genetic insights should be interpreted with a qualified healthcare provider to support more informed conversations about medication selection, expected tolerability, and dosing strategy. Genetic predispositions do not predict exact medication response but can highlight which patients might benefit from closer monitoring or alternative approaches.

The Precision Peptide Genetic Test reveals predispositions in peptide pathway variants (GIPR rs1800437, FTO rs9939609, MC4R rs17782313) that may relate to GLP-1 receptor sensitivity and metabolic risk. This test is available as $298. Combined with clinical biomarkers and provider assessment, these insights can support a more personalized conversation about whether a branded GLP-1, compounded formulation, or dual-peptide approach is most appropriate for your situation.

If you are evaluating GLP-1 options based on cost, efficacy, and personal health factors, consider discussing genetic and biomarker context with your provider alongside pricing information. PlexusDx compounded semaglutide ($189/mo) and tirzepatide ($289/mo) offer lower entry points than branded alternatives, with flexible dosing tailored to your clinical response. The Precision Peptide Genetic Test can support a more informed partnership between you and your provider in selecting the right GLP-1 strategy.

How Your Genetics Relate to GLP-1 Pathways

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, FTO rs9939609, and MC4R rs17782313 — relate to the biological pathways these medications act on. These are pathway-level associations only and do not predict how much weight you will lose or how you will respond to any specific medication. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights so you and your provider can see how your genes relate to these pathways. It does not recommend, prescribe, or determine which medication, dose, or peptide is right for you. The PlexusDx Precision Peptide Genetic Test ($298) gives you and your provider pathway-level genetic context to support a more personalized conversation. Genetics is a guide, not a guarantee.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers seven prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Microdose GLP-1 Protocol is $129/mo flat. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test ($298) to personalize your protocol from day one.

Frequently Asked Questions

Is Ozempic sold as a single shot, or do you buy a month at a time?

Ozempic is not sold as a single shot. The article explains that it is dispensed in multi-dose pens containing four injections rather than individual doses, so the real purchasing unit is a monthly prescription and any per-shot figure is just a pen price divided out. What a given patient actually pays varies with pharmacy, plan and dosage strength, so your pharmacy and insurer are the places to confirm the current cost.

How does Ozempic coverage differ across Medicare, Medicaid and commercial plans?

Coverage varies significantly by plan and by indication. The article says Medicare Part D may cover Ozempic for type 2 diabetes with step therapy requirements, while Medicaid coverage depends on the individual state program. Commercial insurers increasingly cover GLP-1 medications, though many impose prior authorization, quantity limits, or dose escalation protocols to manage costs.

Do uninsured patients have any route to a lower Ozempic cost?

The article points to manufacturer-sponsored programs offering discounted pricing tiers as a possible route for uninsured patients. It separately describes Novo Nordisk's official copay assistance program as capping out-of-pocket costs for eligible individuals who have commercial insurance, which is a different program with different eligibility rules. Confirming which one applies is a conversation with the manufacturer or the pharmacy.

Besides price, what clinical factors does the article say should drive GLP-1 selection?

It says individual metabolic risk profiles and baseline cardiovascular or renal function should guide treatment selection alongside cost. The article lists contraindications that rule the class out entirely, namely a personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia type 2, or severe pancreatitis, and recommends baseline evaluation of renal function, cardiovascular status, and diabetic eye disease.

Do published retail prices reflect what patients actually end up paying?

Often not. The article notes hospital systems and large employers sometimes negotiate direct pricing with manufacturers, creating variation in real patient costs that published retail figures do not capture. Manufacturer rebates, patient assistance programs, and local pharmacy pricing all move the final number, which is why it treats retail listings as a starting reference rather than a quote.

Related Reading

• Cost Of Ozempic Per Month
• Alternatives For Ozempic
• Ozempic Alternatives
• Ozempic Cost 2

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.